Gregory Laurence MD currently operates a surgical and regenerative medical practice near Memphis, TN. He is the founder of Germantown Aesthetics and Gravity Professional Services. His expertise outside of surgery relates to unprecedented clinical applications of biotechnology. These innovations translate to real-world applications for entrepreneurs and corporate leaders. New employee-provided health care strategies will enable businesses to become more successful through utilization of regenerative technology, blockchain and machine learning. This new approach will ensure a higher retention of key team members. Dr. Laurence obtained his undergraduate and doctorate degrees from Baylor University and the University of Texas at Houston Medical School. He completed his residency and fellowship in high-risk obstetrics at the University of Tennessee. He operates a cosmetic surgery and concierge regenerative surgical clinic. He was the keynote speaker for the American Academy of Neurologic and Orthopedic Surgeons related to the future of brain and spine medicine. He has published on prevention of breast implant rippling and on the transaxillary breast augmentation technique. His surgical innovations include the use of biologics to prevent recurrent capsular contracture, ultra-remote breast drainage, and surgical refinements for neo-umbilicoplasty. Dr. Laurence has served as expert witness at trial for the defense and for the plaintiff and has experience with both civil and criminal litigation. He has presented as a defense witness at professional license administrative hearings. He provides consultation services for those physicians who wish to limit human resources (HR), civil, and regulatory risk. Dr. Laurence is currently serving as resident health care expert in the NY-based Financial Policy Counsel. He has presented more than twenty unique lectures for six different medical specialties on topics including surgery, bio-stimulating facial injectables, laser resurfacing, Continuous Quality Improvement, peer review, anesthesia, leadership, and autologous stromal-derived progenitor cells. |